Valuation: Savara Inc

Market Cap 1.07B 958M 885M 802M 1.5B 102B 1.52B 10.65B 4.22B 53.34B 4.02B 3.94B 168B P/E 2026 *
-6.99x
P/E 2027 * -10.8x
Enterprise Value 606M 541M 500M 453M 848M 57.56B 862M 6.02B 2.38B 30.16B 2.28B 2.23B 95.07B EV / Sales 2026 *
339x
EV / Sales 2027 * 9.22x
Free-Float
97.45%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 01/12/2020
Director of Finance/CFO 57 15/07/2026
Chief Tech/Sci/R&D Officer 56 01/12/2023
Director TitleAgeSince
Director/Board Member 59 01/02/2009
Director/Board Member 77 01/10/2010
Director/Board Member 73 01/10/2013
Change 5-day change 1-year change 3-year change Capi.($)
+2.41%+0.29%+42.02%+71.57% 64.69B
-0.15%+7.50%+11.01%+73.48% 54.78B
+0.57%+4.60%+10.07%+92.86% 53.49B
+0.37%+4.67%+27.03%+52.07% 45.98B
-1.21%+2.32%+21.80%+123.81% 42.94B
-0.37%+5.07%+249.91%+918.74% 40.08B
+0.05%+0.21%+18.26%+58.53% 33.52B
-0.38%+5.68%+36.43%+27.54% 23.67B
+1.19%-4.98%+29.01%-0.65% 23.97B
Average +0.28%+2.41%+49.51%+157.55% 42.57B
Weighted average by Cap. +0.39%+2.73%+47.57%+158.58%

Financials

2026 *2027 *
Net sales 1.79M 1.6M 1.48M 1.34M 2.5M 170M 2.55M 17.78M 7.04M 89.07M 6.72M 6.58M 281M 80.69M 72.06M 66.57M 60.33M 113M 7.66B 115M 801M 317M 4.01B 303M 296M 12.65B
Net income -151M -135M -124M -113M -211M -14.32B -214M -1.5B -593M -7.5B -566M -554M -23.65B -94.11M -84.04M -77.64M -70.36M -132M -8.93B -134M -934M -370M -4.68B -353M -346M -14.76B
Net Debt -466M -416M -385M -349M -652M -44.25B -663M -4.63B -1.83B -23.19B -1.75B -1.71B -73.1B -329M -293M -271M -246M -459M -31.18B -467M -3.26B -1.29B -16.34B -1.23B -1.21B -51.51B
Logo Savara Inc
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company's lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Savara Inc